The FDA warns that Novo Nordisk has not reported side effects or death cases related to the weight loss drug Ozempic
Novo Nordisk AS (NVO.US) received a warning letter from the U.S. Food and Drug Administration (FDA) for failing to report all suspected side effects experienced by patients taking its blockbuster weight loss drug Ozempic. The stock price has recently dropped by 3%.
The FDA's letter indicated that the cases included two deaths and one suicide, with patients having received treatment with semaglutide, the generic name for Ozempic and Wegovy. The FDA did not explicitly state whether these deaths or other side effects were related to the drug
Source: AASTOCKS The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments